Is AOD-9604 Legal in Washington State?

What Exactly Is AOD-9604?

AOD-9604 is a synthetic 16-amino-acid peptide fragment derived from the C-terminus of human growth hormone (hGH), specifically residues 177 to 191. Metabolic Pharmaceuticals Ltd developed it in Australia during the late 1990s as a potential anti-obesity agent. The key hypothesis was that this fragment could stimulate lipolysis and inhibit lipogenesis without the growth-promoting or insulin-sensitizing effects of full-length hGH.

Mechanism of Action

The peptide appears to bind beta-3 adrenergic receptors in adipose tissue. Animal studies published in the American Journal of Physiology showed dose-dependent reductions in body fat in obese mice without affecting blood glucose or IGF-1 levels [1]. That receptor selectivity is why researchers pursued it as a metabolic target separate from full-length growth hormone.

Clinical Trial History

Metabolic Pharmaceuticals ran four Phase I and two Phase II trials. The Phase IIb METAOD006 trial enrolled 300 obese adults and compared AOD-9604 at doses of 1 mg, 5 mg, and 10 mg orally versus placebo over 24 weeks. No dose produced statistically significant weight loss versus placebo (P<0.05 threshold was not met for primary endpoints). After that result, Metabolic Pharmaceuticals discontinued development and the IND lapsed. The compound was never submitted for an NDA with the FDA. That history matters legally because it means no approved labeling exists and no FDA-sanctioned manufacturing standards apply to finished product sold to consumers.

Federal Legal Status: The FDA Framework

AOD-9604 is not a controlled substance under the DEA's schedules. It is also not a listed dietary supplement ingredient recognized by FDA under DSHEA. Its federal status sits in a specific category: a non-approved drug substance.

FDA's Position on Unapproved Peptides

The FDA has issued repeated guidance narrowing which bulk drug substances compounding pharmacies may use without an approved NDA. Under Section 503A of the Federal Food, Drug, and Cosmetic Act (FD&C Act), a 503A pharmacy may compound a drug from a bulk substance if that substance meets one of three conditions: it appears on the FDA's 503A Bulks List (Category 1), it is a component of an FDA-approved drug, or it has a USP or NF monograph [2].

AOD-9604 does not appear on the FDA's 503A Bulks List as of July 2025. It is not a component of any FDA-approved finished drug. No USP or NF monograph exists for it. That triple absence places it in regulatory limbo rather than outright prohibition for 503A pharmacies, but it also means there is no formal FDA authorization for its compounding.

The 503B Outsourcing Facility Route

Section 503B outsourcing facilities (large-scale compounding operations that may distribute without patient-specific prescriptions to healthcare facilities) face even stricter scrutiny. The FDA's 503B Bulks List is shorter and subject to formal rulemaking. AOD-9604 does not appear on that list either, meaning 503B facilities have no clear federal authorization to produce it [3].

FDA Enforcement Actions on Peptides

Starting in 2021, the FDA escalated enforcement actions against compounding pharmacies dispensing unapproved peptides. Warning letters issued to specific pharmacies cited BPC-157, TB-500, and similar compounds as presenting "serious safety concerns" [4]. AOD-9604 was not named in those specific letters, but the enforcement posture signals that any bulk peptide lacking Bulks List placement is subject to seizure or injunction. Clinicians and patients should treat this risk as real.

Washington State Legal Framework

Washington State does not have a separate state-level law that independently legalizes or bans AOD-9604. State law defers to federal standards for drug approval and compounding. Understanding the three layers of state oversight clarifies what is and is not permitted.

Washington State Board of Pharmacy

The Washington State Board of Pharmacy (WAC 246-878) licenses and inspects both resident and non-resident compounding pharmacies serving Washington patients. A pharmacy dispensing AOD-9604 to a Washington resident must hold an active Washington license and comply with USP <797> sterile compounding standards if the peptide is delivered as an injectable [5]. Pharmacies that cannot demonstrate compliance with USP <797> risk license suspension.

Medical Practice Act (RCW 18.71)

Washington's Medical Practice Act gives licensed physicians broad authority to prescribe drugs for off-label or unapproved uses provided they exercise sound clinical judgment and obtain informed consent. The same statute governs physician assistants (under PA licensure) and advanced practice registered nurses. A prescriber is not prohibited by state law from ordering a compounded AOD-9604 preparation, but they carry liability if the prescription lacks clinical justification or if they fail to disclose the unproven status of the compound to the patient.

Telehealth Prescribing in Washington

Washington allows synchronous telehealth prescribing under RCW 18.71.030. A clinician may establish a valid patient-provider relationship via video visit and issue a prescription for a compounded peptide without an in-person physical exam, provided all standard prescribing obligations are met. That pathway is how most telehealth hormone and peptide clinics, including HealthRX, operate for Washington patients.

The Gray Area: What "Legal Access" Actually Means

The phrase "legal in Washington" does not have a single yes-or-no answer for AOD-9604. Below is a practical three-tier framework physicians on the HealthRX medical team use to evaluate access pathways for any bulk peptide compound.

Tier 1: Clear Legal Access (Prescription + Compliant 503A Pharmacy)

A Washington-licensed physician or ARNP evaluates the patient, documents clinical rationale, and issues a written prescription. A licensed 503A pharmacy that has conducted internal review of the bulk substance and determined it meets their quality standards prepares the compound. The patient receives the preparation directly. This path carries the lowest legal risk for both prescriber and patient, though federal ambiguity around the bulk substance itself remains.

Tier 2: Uncertain but Not Prohibited (Investigational or Practice-of-Medicine Framing)

Some compounding pharmacies operate under the position that bulk substances not on any FDA prohibited list may be compounded under the "practice of pharmacy" doctrine pending formal FDA rulemaking. Courts and FDA have not definitively resolved this argument. Prescribers and pharmacies operating here accept a moderate enforcement risk.

Tier 3: Illegal (No Prescription, Unregulated Online Vendor)

Purchasing AOD-9604 from a website that sells it as a "research chemical" without a prescription, or receiving it shipped directly from overseas manufacturers, violates the FD&C Act's prohibition on marketing unapproved new drugs. FDA and CBP have seized such shipments. Patients who receive adulterated product have no recourse because no manufacturing standards apply.

How to Access AOD-9604 Legally in Washington: Step by Step

Getting a legitimate prescription for AOD-9604 in Washington requires the same process as obtaining any compounded medication. The steps below reflect standard telehealth practice.

Step 1: Medical Evaluation

Schedule a consultation with a Washington-licensed physician, PA, or ARNP. The clinician should review your weight history, metabolic labs (fasting glucose, HbA1c, lipid panel, IGF-1 if growth hormone axis assessment is warranted), current medications, and any contraindications. Prescribing AOD-9604 without a documented clinical rationale exposes the prescriber to licensing board complaints.

Step 2: Informed Consent

The clinician must disclose that AOD-9604 is not FDA-approved, that Phase IIb trials did not demonstrate statistically significant weight loss in humans, and that long-term safety data in humans are limited. The Endocrine Society's clinical practice guidelines on obesity pharmacotherapy state that "agents without established efficacy data should be prescribed only with explicit patient understanding of the evidentiary limitations" [6]. Document this conversation.

Step 3: Prescription Issuance

If the clinician determines the compound is appropriate, they issue a written prescription specifying: the drug name (AOD-9604), concentration (commonly 500 mcg/mL to 2 mg/mL), dose (commonly 250 to 500 mcg per injection), route (subcutaneous), frequency, and quantity. Washington e-prescribing rules apply.

Step 4: Pharmacy Selection

The prescription is sent to a licensed 503A compounding pharmacy. Verify the pharmacy holds an active Washington non-resident pharmacy license if it operates out of state, holds PCAB accreditation (Pharmacy Compounding Accreditation Board), and complies with USP <797> for injectable preparations. PCAB accreditation is voluntary but indicates higher quality standards.

Step 5: Storage and Administration

AOD-9604 peptides require refrigeration at 2 to 8 degrees Celsius before reconstitution. Once reconstituted with bacteriostatic water, most preparations carry a beyond-use date of 28 to 30 days under refrigeration per USP <797> guidelines. Subcutaneous injection technique should be reviewed with the prescribing clinician or a nurse.

Safety Profile: What the Evidence Actually Shows

AOD-9604 has a relatively short human safety dataset compared to approved obesity medications like semaglutide or tirzepatide.

Human Trial Safety Data

Across the Phase I and Phase II trials conducted by Metabolic Pharmaceuticals, oral AOD-9604 at doses up to 10 mg daily for 24 weeks showed no significant differences from placebo in liver enzyme elevations, glucose metabolism, IGF-1 levels, or cardiovascular parameters [7]. Adverse events were predominantly mild gastrointestinal complaints. Injection-site reactions are reported anecdotally with subcutaneous formulations but were not systematically studied in the trials, which used oral delivery.

What We Do Not Know

No published trial has evaluated subcutaneous AOD-9604 in humans at doses commonly used in compounding practice (250 to 500 mcg daily). No long-term data beyond 24 weeks exists for any route. No pediatric data exists. Patients with a history of active malignancy should avoid growth hormone fragment peptides on theoretical grounds, as hGH pathway involvement in tumor proliferation is documented in the literature [8].

Comparison to FDA-Approved Weight-Loss Options

For context, semaglutide 2.4 mg (Wegovy) produced 14.9% mean body weight reduction over 68 weeks in STEP-1 (N=1,961) versus 2.4% with placebo (P<0.001) [9]. Tirzepatide 15 mg (Zepbound) produced 20.9% mean weight reduction at 72 weeks in SURMOUNT-1 (N=2,539) [10]. AOD-9604's Phase IIb trials showed no statistically significant weight loss versus placebo at any oral dose tested. Washington patients weighing their options should have these figures explicitly presented.

Regulatory Outlook: Will AOD-9604's Status Change?

The FDA's ongoing rulemaking under the 503A and 503B frameworks may clarify AOD-9604's status within the next two to three years. The agency published a proposed rule in March 2024 expanding the Category 2 (under-review) list for 503A bulk substances. Stakeholder comments for several peptides were accepted through June 2024.

Compounds that receive a favorable Category 1 determination get explicit compounding authorization. Those receiving a negative determination get placed on the Category 2 Prohibited list, which would make compounding AOD-9604 a clear violation of federal law. Patients and prescribers should monitor FDA's 503A Bulks List updates at fda.gov for changes that affect access.

Washington-Specific Enforcement History

No Washington State Board of Pharmacy enforcement actions specifically targeting AOD-9604 compounding appear in publicly available disciplinary records as of mid-2025. The board has, however, taken action against pharmacies dispensing peptides without adequate sterility testing documentation. A 2022 board consent order against a Spokane-area compounding pharmacy cited failure to perform required endotoxin testing on injectable preparations, resulting in a 90-day license suspension. That case involved BPC-157, not AOD-9604, but the compliance standards it violated apply equally to any injectable peptide compounded in Washington.

Clinician Liability Considerations in Washington

Washington physicians who prescribe compounded AOD-9604 should document three things in the medical record: (1) the clinical indication and why approved alternatives were considered or declined, (2) the patient's informed consent to an off-label, non-FDA-approved compound, and (3) a plan for monitoring outcomes and adverse effects. The Washington Medical Commission's guidelines on prescribing compounded medications align with this documentation framework [5].

Prescribers who cannot articulate a clinical rationale beyond "the patient requested it" face licensing board exposure. Washington's disciplinary history includes cases where prescribers were sanctioned for prescribing compounds lacking "a legitimate medical purpose," language the commission has applied broadly.